DNMT1 and neoplasm: In a previous study, we employed a CRISPR-Cas9-based loss-of-function screen in a murine SHH-MB cell model (SMB21)15 in order to unravel genetic dependencies for this tumor entity, validating DNA methyltransferase 1 (DNMT1) as a druggable vulnerability in SHH-MB models16.